Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.71 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680974 | 0.92 | CCR2 (0.62) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL6300934 | 0.90 | NOD2 (0.66) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL5679166 | 0.89 | CCR2 (0.57) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL6300560 | 0.89 | NOD2 (0.58) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL6307761 | 0.89 | NOD2 (0.60) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL6302592 | 0.88 | NOD2 (0.57) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL6307920 | 0.88 | CCR2 (0.72) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL6300663 | 0.87 | NOD2 (0.56) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL5679083 | 0.87 | CCR2 (0.54) | CCR2ABCB11NOD2NOD1F10 | |
| SCHEMBL7594730 | 0.87 | NOD2 (0.56) | CCR2ABCB11NOD2NOD1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150952-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-10-27 | — | — | EP | disclosed |
| US-6737435-B1 | ANTIINFLAMMATORY AGENTS; MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) DISEASES | ASTRAZENECA AB (SE) | 2004-05-18 | — | — | US | disclosed |
| EP-1150953-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-6613760-B1 | Compounds such as N-(3,4-Dichlorobenzyl)-2-ethoxycarbonyl-indole-4-carboxylic acid, used as inhibitors of monocyte chemoattractant proteins (MCP-1) and RANTES induced chemotaxis; antiinflammatory agents | ASTRAZENECA AB (SE) | 2003-09-02 | — | — | US | disclosed |
| EP-1150953-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150952-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046197-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| WO-2000046196-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |